tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Invex Therapeutics Expands Research and Streamlines Operations

Story Highlights
  • Invex Therapeutics expanded its collaboration with Tessara to study Exenatide in Alzheimer’s Disease.
  • The company renewed orphan drug designations and managed cash reserves with a focus on R&D.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Invex Therapeutics Expands Research and Streamlines Operations

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Invex Therapeutics Ltd. ( (AU:IXC) ) just unveiled an announcement.

Invex Therapeutics Ltd has expanded its research collaboration with Tessara Therapeutics to explore Exenatide’s potential in Alzheimer’s Disease, with results expected later in 2025. The company renewed orphan drug designations in Europe and the US for Exenatide, attended the Bio 2025 conference to explore partnerships, and is de-registering its UK subsidiary to reduce overheads. Financially, Invex managed its cash reserves with a closing balance of $5.4 million, focusing on R&D activities with a slight decrease in operating cash outflows.

More about Invex Therapeutics Ltd.

Invex Therapeutics Ltd is a biopharmaceutical company that focuses on developing and commercializing Exenatide for neurological conditions related to raised intracranial pressure (ICP). The company is actively involved in research and development, particularly in collaboration with other firms, to explore the potential of Exenatide in treating conditions such as Alzheimer’s Disease and idiopathic intracranial hypertension.

Average Trading Volume: 51,964

Technical Sentiment Signal: Buy

Current Market Cap: A$6.76M

See more data about IXC stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1